Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
The use of intrathecal (IT) methotrexate (MTX) in combination with systemic high-dose (HD) MTX is an established procedure for central nervous system prophylaxis in patients with acute lymphoblastic leukemia, but the evidence for the necessity of this combination is not convincing. The MTX concentration in the cerebrospinal fluid (CSF) was evaluated in 138 samples from children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. CSF samples were obtained by lumbar puncture 12-24 hours after starting the HD MTX infusion (5 g/m2 over 24 hours) and immediately before the IT administration of MTX. Serum MTX concentrations at the end of infusion were assessed by routine therapeutic drug monitoring. Cytotoxic MTX concentrations of 1 microM or greater were detected in 81.2% of CSF samples. CSF MTX concentrations were significantly lower in samples from patients younger than 7 years. The correlation between MTX concentrations in the serum and the CSF was moderate (r = 0.451) and became stronger with increasing age. The median CSF MTX concentrations per cycle were comparable (1.40, 1.25, 1.39, 1.38 microM for cycles 1-4, respectively). The predictive value and the accuracy of the CSF MTX concentration measured during the first cycle of HD MTX in respect to concentrations in the following cycles were high (94.4% and 85.7%, respectively) suggesting that the CSF MTX concentration during the first HD MTX infusion is a useful predictor for sufficient CSF MTX concentrations in the following HD MTX cycles. Our results confirm previously published data on MTX accumulation in the CSF after 5 g/m2 MTX over 24 hours in an independent cohort monitored in a real-life setting. Based on the common opinion that 1 microM represents the minimal antileukemic MTX concentration, current data warrant reevaluation of the necessity of routine IT MTX following HD MTX. Our findings offer a perspective on reducing the burden of IT MTX in children on consolidation therapy by CSF MTX drug monitoring.
Niemann
Andreas
A
Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany.
Mühlisch
Jörg
J
Frühwald
Michael C
MC
Gerss
Joachim
J
Hempel
Georg
G
Boos
Joachim
J
D000293:Adolescent; D000375:Aging / Q000378:metabolism; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000134:cerebrospinal fluid*; D001711:Biotransformation; D002648:Child; D002675:Child, Preschool; D016903:Drug Monitoring; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007278:Injections, Spinal; D007938:Leukemia / Q000097:blood / Q000188:drug therapy; D013058:Mass Spectrometry; D008727:Methotrexate / Q000008:administration & dosage / Q000134:cerebrospinal fluid*; D009369:Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy; D012189:Retrospective Studies; D018570:Risk Assessment; D055815:Young Adult
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate